Neurofibromatosis Clinical Trials 2024

What are the top hospitals conducting Neurofibromatosis research?

When it comes to advancing research and treatment options for Neurofibromatosis, several top hospitals are making significant strides. One such institution is the National Institutes of Health (NIH) Clinical Center in Bethesda. With nine active clinical trials focusing on Neurofibromatosis and a total of 20 trials conducted over time, the NIH Clinical Center has been at the forefront of studying this complex condition since their first recorded trial in 2005. In Cincinnati, the Children's Hospital Medical Center also plays a pivotal role in Neurofibromatosis research. They currently have nine ongoing clinical trials dedicated to understanding and treating this condition, with a history of 21 completed trials dating back to 2005.

Meanwhile, in Washington D.C., researchers at Children's National Medical Center are actively engaged in eight clinical trials for Neurofibromatosis while having previously contributed to 20 studies since initiating their first trial in 2002. On the West Coast, Children's Hospital Los Angeles is conducting seven active clinical trials focused on finding new treatments for neurofibromas through innovative approaches; they have already completed thirteen successful investigations since entering into researching about this disorder from starting year as late as2009.In Philadelphia's Children's Hospital stands another powerhouse driving advancements against Neurofibromatosis with seven ongoing clinical trials and an impressive history of nineteen previous studies conducted since recording their inaugural trial backin early millennium days -in earlier dates specifically set around yearas old as2001.

These leading hospitals stand out not only for their dedication but also for paving the way towards better understanding and management strategies when it comes tonNeurofibroma-related conditions like NF1and NF2.These efforts signify hope for individuals affected by these rare genetic disorders across different regions within United States,and ultimately contribute towards improving quality life overallfor everyone globally who may find themselves impacted by these conditions.Physicians,researchers,and patients alike can rest assured that these institutions are at the forefront of bringing about positive change in the fight against Neurofibromatosis.

Which are the best cities for Neurofibromatosis clinical trials?

When it comes to Neurofibromatosis clinical trials, several cities emerge as prominent locations for cutting-edge research. With 20 active trials, Boston, Massachusetts leads the way with studies focusing on Stress and Symptom Management Program 2, dabrafenib, Selumetinib Sulfate, and other promising treatments. Following closely behind is Los Angeles, California with 18 ongoing trials investigating Lenalidomide, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, Binimetinib, and more. New york City also stands out with 16 active trials exploring Lenalidomide, Trametinib, Open Label Continuous Treatment regimens among others. These cities along with Bethesda Maryland and Chicago Illinois provide individuals with Neurofibromatosis access to a diverse range of clinical trials that pave the path for advancements in treatment options and improved outcomes.

Which are the top treatments for Neurofibromatosis being explored in clinical trials?

Clinical trials for Neurofibromatosis are paving the way for potential breakthroughs in treatment. Among the top contenders is selumetinib, which has shown promise with four ongoing trials and a total of ten Neurofibromatosis studies since its introduction in 2010. Another noteworthy candidate is the Stress and Symptom Management Program 2, currently being explored in two active trials after its listing in 2017. Additionally, selumetinib sulfate and trametinib hold promising positions with two active trials each, while aminolevulinic acid demonstrates potential through one ongoing trial. These innovative treatments offer hope to patients battling this challenging condition.

What are the most recent clinical trials for Neurofibromatosis?

Exciting advancements are being made in the field of neurofibromatosis, with recent clinical trials providing hope for improved treatment options. One such trial focuses on the efficacy of a flu and total body irradiation (TBI) regimen as a potential therapy for neurofibromatosis patients. Another study explores the use of erenumab-Aooe specifically for neurofibromatosis, aiming to evaluate its effectiveness in managing symptoms. Additionally, doxycycline injection and DPCP have shown promise in early phases as potential treatments for this condition. These trials offer valuable insights into new approaches that may enhance the lives of individuals living with neurofibromatosis.

What Neurofibromatosis clinical trials were recently completed?

Recently, there have been notable advancements in clinical trials for neurofibromatosis, a genetic disorder that causes tumors to develop along nerves. One significant trial involved the investigation of a potential treatment called Selumetinib, sponsored by AstraZeneca PLC and completed in June 2021. Another noteworthy study focused on Everolimus as a therapeutic option and was conducted by the National Cancer Institute (NCI), reaching completion in February 2020. These recent clinical trials signify progress towards finding effective treatments for neurofibromatosis patients, offering hope for improved outcomes and quality of life.